Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2517205 | 0.79 | ALDH1A1 (0.33) | MEN1MAPTKMT2AALDH1A1LMNA | |
| SCHEMBL8579610 | 0.78 | MEN1 (0.33) | MEN1MAPTKMT2AALDH1A1LMNA | |
| SCHEMBL21721608 | 0.64 | PTGS2 (0.32) | KMT2A | |
| SCHEMBL29239535 | 0.62 | CA1 (0.34) | MEN1MAPTKMT2AALDH1A1LMNA | |
| SCHEMBL9830480 | 0.58 | — | — | |
| SCHEMBL4892445 | 0.58 | — | — | |
| SCHEMBL6342720 | 0.58 | PKM (0.34) | — | |
| SCHEMBL6335694 | 0.58 | ALDH1A1 (0.37) | MAPTALDH1A1LMNA | |
| SCHEMBL15244134 | 0.57 | ERN1 (0.33) | ALDH1A1 | |
| SCHEMBL6335267 | 0.57 | CYP1A2 (0.42) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1291345-B1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6924276-B2 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| US-20030087924-A1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | SORENSON RODERICK JOSEPH (US) | 2003-05-08 | — | — | US | disclosed |
| EP-1291345-A1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087924-A1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP3, MMP9 | MEN1 1987/4885MAPT 4511/4885KMT2A 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.